Processing

Please wait...

Settings

Settings

Goto Application

1. WO2018219619 - METHOD FOR MODIFYING MICROCYSTINS AND NODULARINS

Publication Number WO/2018/219619
Publication Date 06.12.2018
International Application No. PCT/EP2018/062156
International Filing Date 09.05.2018
Chapter 2 Demand Filed 08.03.2019
IPC
C12P 13/00 2006.1
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
13Preparation of nitrogen-containing organic compounds
C12P 21/04 2006.1
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
21Preparation of peptides or proteins
02having a known sequence of two or more amino acids, e.g. glutathione
04Cyclic or bridged peptides or polypeptides, e.g. bacitracin
C07D 259/00 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
259Heterocyclic compounds containing rings having more than four nitrogen atoms as the only ring hetero atoms
C07K 7/58 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
7Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
50Cyclic peptides containing at least one abnormal peptide link
54with at least one abnormal peptide link in the ring
56the cyclisation not occurring through 2,4-diamino-butanoic acid
58Bacitracins; Related peptides
CPC
A61K 47/64
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
50the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
51the non-active ingredient being a modifying agent
62the modifying agent being a protein, peptide or polyamino acid
64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
A61K 47/6829
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
50the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
51the non-active ingredient being a modifying agent
68the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
6801Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
6803Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
6811the drug being a protein or peptide, e.g. transferrin or bleomycin
6817Toxins
6829Bacterial toxins, e.g. diphteria toxins or Pseudomonas exotoxin A
C07K 7/56
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
7Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
50Cyclic peptides containing at least one abnormal peptide link
54with at least one abnormal peptide link in the ring
56the cyclisation not occurring through 2,4-diamino-butanoic acid
C07K 7/58
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
7Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
50Cyclic peptides containing at least one abnormal peptide link
54with at least one abnormal peptide link in the ring
56the cyclisation not occurring through 2,4-diamino-butanoic acid
58Bacitracins; Related peptides
C12N 1/20
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
1Microorganisms, e.g. protozoa; Compositions thereof
20Bacteria
C12N 2500/32
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
2500Specific components of cell culture medium
30Organic components
32Amino acids
Applicants
  • CYANO BIOTECH GMBH [DE]/[DE]
Inventors
  • ENKE, Heike
  • LORENZEN, Wolfram
  • JAHNS, Stefan
  • ENKE, Dan
  • NIEDERMEYER, Timo
  • MOSCHNY, Julia
Agents
  • ANDRESEN, Heiko
Priority Data
17170284.809.05.2017EP
Publication Language English (en)
Filing Language English (EN)
Designated States
Title
(EN) METHOD FOR MODIFYING MICROCYSTINS AND NODULARINS
(FR) PROCÉDÉ DE MODIFICATION DE MICROCYSTINES ET DE NODULARINES
Abstract
(EN) The invention relates to a method of producing a modified non-ribosomal peptide, e.g. a modified microcystin and/or modified nodularin (together CA), comprising the steps of: a) growing a modified non-ribosomal peptide producing cyanobacteria strain in a culture media, b) adding one or more modified substrates preferably modified amino acids to said culture, and c) inoculating the non- ribosomal peptide producing strain the presence of said modified substrates. The thus modified non- ribosomal peptide may be used for the therapy of various diseases.
(FR) L'invention concerne un procédé de production d'un peptide non ribosomique modifié, par exemple une microcystine modifiée et/ou une nodularine modifiée (conjointement CA), comprenant les étapes suivantes : a) croissance d'un peptide non ribosomique modifié produisant une souche de cyanobactéries dans un milieu de culture, b) ajout d'un ou plusieurs substrats modifiés de préférence des acides aminés modifiés à ladite culture, et c) inoculation de la souche produisant le peptide non ribosomique en présence desdits substrats modifiés. Le peptide non ribosomique ainsi modifié peut être utilisé pour la thérapie de différentes maladies.
Related patent documents
IL270522This application is not viewable in PATENTSCOPE because the national phase entry has not been published yet or the national entry is issued from a country that does not share data with WIPO or there is a formatting issue or an unavailability of the application.
Latest bibliographic data on file with the International Bureau